This article appeared June 11 in the online edition of ADVANCE.
1. Raynaud’s – Why the Name? Raynaud’s and Scleroderma Association website. http://www.raynauds.org.uk/raynauds/why-the-name
2. Wigley FM. Raynaud’s phenomenon. N Engl J Med. 2002;347(13):1001-1008.
3. Cooke JP, Marshall JM. Mechanisms of Raynaud’s disease. Vasc Med. 2005;10:293-307.
4. Raynaud’s Phenomenon. Federation of European Scleroderma Associations.
http://www.fesca-scleroderma.eu/sites/all/themes/fesca/worldcongress/docs/wigley_en.pdf
5. Brashers VL. Alterations of cardiovascular function. In: McCance KL, Huether SE. Pathophysiology, The Biologic Basis for Disease in Adults and Children. 6th ed. Maryland Heights, MO: Mosby; 2010;1148-1149
6. Pope JE. The diagnosis and treatment of Raynaud’s phenomenon: A practical approach. Drugs. 2007;67(4):517-525.
7. Creager MA, Loscalzo J. Vascular Diseases of the Extremities. In: Fauci AS, et al, eds. Harrison’s Principles of Internal Medicine. 18th ed. New York, NY: McGraw-Hill Professional Pub; 2012: 2071-2072.
8. DiGiacomo RA, et al. Fish-oil dietary supplementation in patients with Raynaud’s phenomenon: a double-blind, controlled, prospective study. Am J Med. 1989;86(2):158-6